Intercept Pharmaceuticals Inc (NASDAQ:ICPT)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research report issued on Friday. They presently have a $231.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 100.42% from the stock’s current price.

Other research analysts have also issued reports about the company. Citigroup Inc set a $240.00 price objective on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 28th. Oppenheimer Holdings Inc. set a $200.00 price objective on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, February 11th. Cowen and Company reiterated a “buy” rating and issued a $225.00 price objective on shares of Intercept Pharmaceuticals in a research report on Monday, April 24th. Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, February 23rd. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 price objective for the company in a research report on Friday, May 5th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $188.76.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 115.26 on Friday. Intercept Pharmaceuticals has a 12-month low of $96.63 and a 12-month high of $177.93. The stock’s market cap is $2.88 billion. The company’s 50-day moving average price is $112.74 and its 200-day moving average price is $113.13.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share for the quarter, topping the consensus estimate of ($4.27) by $0.66. The company had revenue of $21 million during the quarter, compared to analyst estimates of $15.88 million. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The firm’s revenue for the quarter was up 4566.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($5.17) earnings per share. On average, equities analysts expect that Intercept Pharmaceuticals will post ($14.65) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/05/26/intercept-pharmaceuticals-inc-icpt-receives-outperform-rating-from-wedbush.html.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 254 shares of the firm’s stock in a transaction on Monday, February 27th. The stock was sold at an average price of $119.48, for a total value of $30,347.92. Following the sale, the insider now directly owns 21,695 shares in the company, valued at $2,592,118.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO David Shapiro sold 558 shares of the firm’s stock in a transaction on Monday, April 10th. The shares were sold at an average price of $108.51, for a total value of $60,548.58. Following the completion of the sale, the chief marketing officer now owns 45,465 shares in the company, valued at $4,933,407.15. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,318 shares of company stock worth $375,832. 9.20% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of ICPT. WFG Advisors LP boosted its stake in Intercept Pharmaceuticals by 197.1% in the fourth quarter. WFG Advisors LP now owns 2,956 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 1,961 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. US Bancorp DE purchased a new stake in Intercept Pharmaceuticals during the first quarter worth approximately $130,000. Quantbot Technologies LP purchased a new stake in Intercept Pharmaceuticals during the first quarter worth approximately $170,000. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in Intercept Pharmaceuticals by 39.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,630 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 462 shares during the period. Institutional investors and hedge funds own 82.28% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

12 Month Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.